Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer

被引：53

作者：

Xie, Ya ^{[1
]}

Peng, Zheng ^{[1
]}

Shi, Mingxing ^{[1
]}

Ji, Mei ^{[1
]}

Guo, Hongjun ^{[1
]}

Shi, Huirong ^{[1
]}

机构：

[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan, Peoples R China

来源：

MOLECULAR MEDICINE REPORTS | 2014年 / 10卷 / 05期

关键词：

metformin; cisplatin-resistant ovarian cancer; p38; MAPK; cell proliferation; AMPK ACTIVATION; IN-VITRO; PATHWAY; CHEMOTHERAPY; GROWTH; CELLS; EXPRESSION; DECREASES; VIVO;

D O I：

10.3892/mmr.2014.2490

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen-activated protein kinase (MAPK) inhibitor, on. the sensitivity of cisplatin-resistant ovarian cancer to cisplatin. The expression and distribution of phosphorylated p38 MAPK (P-p38 MAPK) was confirmed in drug-resistant and primary ovarian cancer tissues by immunohistochemistry and western blotting. A bromodeoxyuridine ELISA kit was used to analyze the effects of metformin, SB203580, a p38 MAPK inhibitor, and metformin combined with SB203580, on the cell proliferation of SKOV3/DDP cisplatin-resistant ovarian cancer cells. The protein expression of P-p38 MAPK was significantly higher in cisplatin-resistant ovarian cancer, as compared with the primary ovarian cancer tissues. Metformin combined with SB203580 significantly enhanced the sensitivity of SKOV3/DDP cells to cisplatin. In conclusion, the p38 MAPK-signaling pathway may be associated with cisplatin-resistant ovarian cancer. Metformin, combined with the p38 MAPK inhibitor, significantly increased the sensitivity of SKOV3/DDP cells to cisplatin treatment.

引用

页码：2346 / 2350

页数：5

共 50 条

[21] Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer [J].

Zhang, Fuquan ;

Shen, Mingjing ;

Yang, Li ;

Yang, Xiaodong ;

Tsai, Ying ;

Keng, Peter C. ;

Chen, Yongbing ;

Lee, Soo Ok ;

Chen, Yuhchyau .

CANCER BIOLOGY & THERAPY, 2017, 18 (08) :606-615

[22] Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity [J].

Rashed, Laila A. ;

Hashem, Reem M. ;

Soliman, Hala M. .

BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (07) :474-480

[23] Neuronal p38 MAPK Signaling Contributes to Cisplatin-Induced Peripheral Neuropathy [J].

Goel, Yugal ;

Argueta, Donovan A. ;

Peterson, Kristen ;

Lomeli, Naomi ;

Bota, Daniela A. ;

Gupta, Kalpna .

ANTIOXIDANTS, 2025, 14 (04)

[24] Tanshinone II A Facilitates Chemosensitivity of Osteosarcoma Cells to Cisplatin via Activation of p38 MAPK Pathway [J].

Xie, Da-ming ;

Li, Zhi-yun ;

Ren, Bing-kai ;

Gong, Rui ;

Yang, Dong ;

Huang, Sheng .

CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2025, 31 (04) :326-335

[25] Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage [J].

Francescato, Heloisa D. C. ;

Costa, Roberto S. ;

da Silva, Cleonice G. A. ;

Coimbra, Terezila M. .

LIFE SCIENCES, 2009, 84 (17-18) :590-597

[26] Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells [J].

Chun, Jaemoo .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)

[27] Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153 [J].

Wu, N. ;

Gu, C. ;

Gu, H. ;

Hu, H. ;

Han, Y. ;

Li, Q. .

NEOPLASMA, 2011, 58 (06) :482-490

[28] Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival [J].

Sooman, Linda ;

Lennartsson, Johan ;

Gullbo, Joachim ;

Bergqvist, Michael ;

Tsakonas, Georgios ;

Johansson, Fredrik ;

Edqvist, Per-Henrik ;

Ponten, Fredrik ;

Jaiswal, Archita ;

Navani, Sanjay ;

Alafuzoff, Irina ;

Popova, Svetlana ;

Blomquist, Erik ;

Ekman, Simon .

MEDICAL ONCOLOGY, 2013, 30 (03)

[29] Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway [J].

Yong, Lei ;

Ma, Yunlong ;

Zhu, Bin ;

Liu, Xiao ;

Wang, Peng ;

Liang, Chen ;

He, Guanping ;

Zhao, Zhigang ;

Liu, Zhongjun ;

Liu, Xiaoguang .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) :1009-1020

[30] LIMD1 Increases the Sensitivity of Lung Adenocarcinoma Cells to Cisplatin via the GADD45α/p38 MAPK Signaling Pathway [J].

Zeng, Xiaofei ;

Wang, Hong ;

He, Dongsheng ;

Jia, Weikun ;

Ma, Ruidong .

FRONTIERS IN ONCOLOGY, 2020, 10

← 1 2 3 4 5 →